CytoDyn CYDY
OTC CYDY
$0.23 +0.00 (+0.00%)
At close: Nov 11, 2026 · 4:00 PM EST

CytoDyn (CYDY) Gains from Sales and Divestitures (2011 - 2013)

Updated

CytoDyn (CYDY) recorded Gains from Sales and Divestitures of -$583.00 in FY2015 (year ended May 31, 2015).

Analysis

CytoDyn (CYDY) Gains from Sales and Divestitures (2011 - 2013) Analysis & Trends

  • The FY2015 figure is the lowest annual Gains from Sales and Divestitures since FY2012.
  • Per Business Quant data, CYDY's Gains from Sales and Divestitures was -$2,560 in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 CytoDyn 334.50 Mn 285.65 Mn -
Historic Data

Historic Data

Download Data
DateValue
Aug 31, 2013 2,560.00
May 31, 2013 -586.00
Nov 30, 2012 -290.00
Aug 31, 2012 3,436.00
May 31, 2012 293.00
Feb 29, 2012 293.00
Nov 30, 2011 290.00
Aug 31, 2011 -3,436.00
API Access

CytoDyn Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CYDY&period=max&api_key=YOUR_API_KEY